NCT05775874View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

PHASE2RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
Urothelial Carcinoma
Interventions
DRUG

AZD4547

Initiation dose: 80mg BID,po.

DRUG

Tislelizumab

Tislelizumab:200mg Q3W

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY

NCT05775874 - A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC | Biotech Hunter | Biotech Hunter